Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting BRAF-mutant non-small cell lung cancer: Current status and future directions.

Lung cancer (Amsterdam, Netherlands) - 1 Jul 2022

Riudavets Mariona, Cascetta Priscilla, Planchard David

Abstract excerpt

Lung cancer harbouring BRAF mutations accounts for 4% of all non-small cell lung cancer (NSCLC) cases, identifying a relevant subset of patients that need to be promptly managed. Three subtypes of BRAF mutations have been described: class I (V600E), and class II and III (non-V600), with different prognostic and predictive outcomes. Pivotal phase II trials have demonstrated the efficacy of the double BRAF/MEK...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Lung Neoplasms
Share to Mitogen-Activated Protein Kinase Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Oximes

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Source

Identifiers

PMID: 35696864
DOI: 10.1016/j.lungcan.2022.05.014

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting BRAF-mutant non-small cell lung cancer: Current status and future directions.PMID 35696864Read ↗

How far we have come targeting BRAF-mutant non-small cell lung cancer (NSCLC).Semantic proximity Read ↗

Targeting BRAF-Mutant Non-Small Cell Lung Cancer: From Molecular Profiling to Rationally Designed Therapy.Semantic proximity Read ↗

Navigating Therapeutic Challenges in BRAF-Mutated NSCLC: Non-V600 Mutations, Immunotherapy, and Overcoming Resistance.Semantic proximity Read ↗

RAF and MEK Inhibitors in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Advances in anti-BRAF therapies for lung cancer.Semantic proximity Read ↗

Ongoing progress in BRAF-mutated non-small cell lung cancer.Semantic proximity Read ↗

Biology and Clinical Management of Non-V600 BRAF Alterations in NSCLC.Semantic proximity Read ↗

Pathways and targeting avenues of BRAF in non-small cell lung cancer.Semantic proximity Read ↗

Dabrafenib in combination with trametinib in the treatment of patients with BRAF V600-positive advanced or metastatic non-small cell lung cancer: clinical evidence and experience.Semantic proximity Read ↗

BRAF mutant non-small cell lung cancer and treatment with BRAF inhibitors.Semantic proximity Read ↗

[Progress of BRAF Gene Alteration in Non-small Cell Lung Cancer].Semantic proximity Read ↗

Cutting edge therapies: A review of Food and Drug Administration-approved drugs for non-small cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.